Form 8.3 - Abbvie Inc
December 18 2019 - 10:19AM
Dow Jones News
TIDM0QCV TIDM0Y7T
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING
1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) State Street Global Advisors &
Affiliates
--------------------------------------------- -------------------------------
Company dealt in AbbVie Inc.
--------------------------------------------- -------------------------------
Class of relevant security to which US$0.01 common stock
the dealings being disclosed relate (Note 2)
--------------------------------------------- -------------------------------
Date of dealing 17(th) December 2019
--------------------------------------------- -------------------------------
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of
relevant security dealt in (Note 3)
Long Short
------------------------------------- -------------------- -----------
Number (%) Number (%)
------------------------------------- ---------- -------- ------ ---
(1) Relevant securities 68,498,695 4.63183%
------------------------------------- ---------- -------- ------ ---
(2) Derivatives (other than options) N/A
------------------------------------- ---------- -------- ------ ---
(3) Options and agreements to
purchase/sell N/A
------------------------------------- ---------- -------- ------ ---
Total 68,498,695 4.63183%
------------------------------------- ---------- -------- ------ ---
(b) Interests and short positions in relevant securities of the company,
other than the class dealt in (Note 3)
Class of relevant security: Long Short
------------------------------------------- ----------- -----------
Number (%) Number (%)
------------------------------------------- ------ --- ------ ---
(1) Relevant securities N/A
------------------------------------------- ------ --- ------ ---
(2) Derivatives (other than options) N/A
------------------------------------------- ------ --- ------ ---
(3) Options and agreements to purchase/sell N/A
------------------------------------------- ------ --- ------ ---
Total N/A
------------------------------------------- ------ --- ------ ---
3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 5)
-------------- ----------------------------- -----------------------
Purchase 149,000 42.25
-------------- ----------------------------- -----------------------
Purchase 4,500 89.93
-------------- ----------------------------- -----------------------
Purchase 24,997 90.08
-------------- ----------------------------- -----------------------
Purchase 1,428 90.08
-------------- ----------------------------- -----------------------
Purchase 16,032 90.08
-------------- ----------------------------- -----------------------
Purchase 226 90.08
-------------- ----------------------------- -----------------------
Purchase 27,645 90.08
-------------- ----------------------------- -----------------------
Purchase 1,445 90.08
-------------- ----------------------------- -----------------------
Purchase 51 90.08
-------------- ----------------------------- -----------------------
Purchase 1,117 90.08
-------------- ----------------------------- -----------------------
Purchase 1,117 90.08
-------------- ----------------------------- -----------------------
Purchase 2,144 90.08
-------------- ----------------------------- -----------------------
Purchase 1,440 90.08
-------------- ----------------------------- -----------------------
Purchase 2,236 90.08
-------------- ----------------------------- -----------------------
Purchase 96 89.47
-------------- ----------------------------- -----------------------
Sale 500 89.79
-------------- ----------------------------- -----------------------
Sale 149,000 42.25
-------------- ----------------------------- -----------------------
Sale 430 90.08
-------------- ----------------------------- -----------------------
Sale 505 90.08
-------------- ----------------------------- -----------------------
Sale 3,700 90.08
-------------- ----------------------------- -----------------------
Sale 21,264 90.08
-------------- ----------------------------- -----------------------
Sale 42,084 90.08
-------------- ----------------------------- -----------------------
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant securities Price per unit
e.g. CFD (Note 6) (Note 7) (Note 5)
------------- --------------------- ----------------------------- --------------
N/A
------------- --------------------- ----------------------------- --------------
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, Writing, selling, Number of Exercise Type, e.g. Expiry Option money
e.g. call option purchasing securities to which price American, date paid/received
varying etc. the option relates European etc. per unit (Note 5)
(Note 7)
----------------- ----------------- -------------------- -------- -------------- ------ ------------------
N/A
----------------- ----------------- -------------------- -------- -------------- ------ ------------------
(ii) Exercising
Product name, Number of securities Exercise price per
e.g. call option unit (Note 5)
----------------- -------------------- ------------------
N/A
----------------- -------------------- ------------------
(d) Other dealings (including transactions in respect of new securities)
(Note 4)
Nature of transaction Details Price per unit
(Note 8) (if applicable) (Note 5)
--------------------- ------- -------------------------
N/A
--------------------- ------- -------------------------
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or
derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any other person
relating to the voting rights of any relevant securities
under any option referred to on this form or relating
to the voting rights or future acquisition or disposal
of any relevant securities to which any derivative
referred to on this form is referenced. If none, this
should be stated.
-----------------------------------------------------------
N/A
-----------------------------------------------------------
Is a Supplemental Form 8 attached? (Note 9) NO
------------------------------------------------------- --------------------
Date of disclosure 18(th) December 2019
------------------------------------------------------- --------------------
Contact name Colin Fernandes
------------------------------------------------------- --------------------
Telephone number 020 33956221
------------------------------------------------------- --------------------
If a connected EFM, name of offeree/offeror with which N/A
connected
------------------------------------------------------- --------------------
If a connected EFM, state nature of connection (Note N/A
10)
------------------------------------------------------- --------------------
(END) Dow Jones Newswires
December 18, 2019 10:04 ET (15:04 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Allergan (NYSE:AGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Allergan (NYSE:AGN)
Historical Stock Chart
From Sep 2023 to Sep 2024
